AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27145292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24224808 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 1 week
Number of subjects: 180
Study 24224808 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 2 weeks
Number of subjects: 180
Study 24224808 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., metronidazole 250 mg b.i.d., and sitafloxacin 100 mg b.i.d. (RMS) for 1 week
Number of subjects: 180
Study 24224808 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., metronidazole 250 mg b.i.d., and sitafloxacin 100 mg b.i.d. (RMS) for 2 weeks
Number of subjects: 180
Study 22209180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection of 8 mg dexamethasone
Number of subjects: 20
Study 22209180 — intervention group
Group type: COMPARATOR
Intervention: Consumption of 8 mg dexamethasone
Number of subjects: 20
Study 20353116 — intervention group
Group type: EXPERIMENTAL
Intervention: Guangming (GB 37)
Number of subjects: 0
Study 20353116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hegu (LI 4)
Number of subjects: 0
Study 18182457 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated-IFN-alpha2b
Number of subjects: 90
Study 18182457 — intervention group
Group type: COMPARATOR
Intervention: antiretroviral therapy alone
Number of subjects: 90
Study 16437191 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet (Group A)
Number of subjects: 745
Study 16437191 — intervention group
Group type: COMPARATOR
Intervention: Current practice (Group B)
Number of subjects: 745
Study 16437191 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 745
Study 14571490 — intervention group
Group type: EXPERIMENTAL
Intervention: aSIC-C stent
Number of subjects: 485
Study 14571490 — intervention group
Group type: COMPARATOR
Intervention: Conventional stainless steel stent
Number of subjects: 485
Study 10759077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing sensitivity deterioration defined as an average deterioration of 10 dB/5 years at 3-4 kHz in at least one ear.
Number of subjects: 705
Study 10759077 — intervention group
Group type: COMPARATOR
Intervention: Age group 41-50 years
Number of subjects: 705
Study 10759077 — intervention group
Group type: COMPARATOR
Intervention: Gender (Males)
Number of subjects: 705
Study 10759077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing sensitivity at 3-4 kHz
Number of subjects: 705
Study 10759077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing sensitivity at 0.5-2 kHz
Number of subjects: 705
Study 9299805 — intervention group
Group type: COMPARATOR
Intervention: BIGCBT without medication
Number of subjects: 106
Study 9299805 — intervention group
Group type: EXPERIMENTAL
Intervention: BIGCBT plus anti-anxiety medication
Number of subjects: 106
Study 9299805 — intervention group
Group type: EXPERIMENTAL
Intervention: BIGCBT plus anti-depressant medication
Number of subjects: 106
Study 9299805 — intervention group
Group type: EXPERIMENTAL
Intervention: BIGCBT plus combined anti-anxiety and anti-depressant medications
Number of subjects: 106
Study 9299805 — intervention group
Group type: EXPERIMENTAL
Intervention: BIGCBT (with or without pharmacotherapy)
Number of subjects: 106
Study 9299805 — intervention group
Group type: EXPERIMENTAL
Intervention: BIGCBT with pre-existing pharmacotherapy
Number of subjects: 106
Study 8436059 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid aerosol inhaler used instead of a cigarette whenever the urge to smoke occurred during the first 12 days of the cessation period.
Number of subjects: 74
Study 8436059 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid aerosol inhaler
Number of subjects: 74
Study 3091405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg)
Number of subjects: 24
Study 30223139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Cognitive Therapy for recurrent depression
Number of subjects: 264
Study 30223139 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of habitual relative to functional responses on the DAS
Number of subjects: 264
Study 30223139 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 264
Study 29804406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope positioning laryngeal mask
Number of subjects: 120
Study 29804406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound positioning laryngeal mask
Number of subjects: 120
Study 29804406 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard positioning laryngeal mask
Number of subjects: 120
Study 26739717 — intervention group
Group type: EXPERIMENTAL
Intervention: KB003 (400 mg)
Number of subjects: 160
Study 26739717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26739717 — intervention group
Group type: EXPERIMENTAL
Intervention: KB003 in eosinophilic asthmatics
Number of subjects: 160
Study 26739717 — intervention group
Group type: COMPARATOR
Intervention: Placebo in eosinophilic asthmatics
Number of subjects: 160
Study 26739717 — intervention group
Group type: EXPERIMENTAL
Intervention: KB003 in patients with FEV1 reversibility ≥ 20%
Number of subjects: 160
Study 26739717 — intervention group
Group type: EXPERIMENTAL
Intervention: KB003 in patients with prebronchodilator FEV1 ≤ 50% predicted
Number of subjects: 160
Study 24472704 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (single-dose and repeated intake)
Number of subjects: 10
Study 24472704 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (repeated intake)
Number of subjects: 10
Study 22718590 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (IL) protocol with implants (tioLogic; Dentaurum, Ispringen, Germany)
Number of subjects: 25
Study 22718590 — intervention group
Group type: COMPARATOR
Intervention: Control group (K1)
Number of subjects: 25
Study 20718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 1000 mg IM)
Number of subjects: 184
Study 20718771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 17620637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day for 5 days/month, repeated monthly for a maximum of 4 months
Number of subjects: 49
Study 17620637 — intervention group
Group type: COMPARATOR
Intervention: Glucantime 60 mg/kg intramuscular for 20 days
Number of subjects: 49
Study 15840739 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 or 40 microg)
Number of subjects: 61
Study 15840739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11973184 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (bolus 1 microg/kg; infusion 0.1‐0.2 microg x kg(‐1) x min(‐1))
Number of subjects: 81
Study 11973184 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg, and 1 microg/kg every 45 min)
Number of subjects: 81
Study 11973184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Remifentanil and Fentanyl
Number of subjects: 81
Study 8197844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment for 10 days postoperatively
Number of subjects: 57
Study 8197844 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 3581699 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline washout
Number of subjects: 20
Study 3581699 — intervention group
Group type: COMPARATOR
Intervention: Control group (intra-articular saline injection)
Number of subjects: 20
Study 31685500 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga + usual care
Number of subjects: 80
Study 31685500 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 28420550 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6mgkg‐1)
Number of subjects: 8
Study 28420550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 100 mg every other week
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every other week
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every other week
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 100 mg every week
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every week
Number of subjects: 301
Study 24550171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sarilumab doses
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab treatment groups
Number of subjects: 301
Study 24550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 301
Study 22951281 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention involving non-GP staff in GP practices
Number of subjects: 60
Study 22951281 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 GP practices without the intervention)
Number of subjects: 60
Study 20949263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (Amonate FDC tablets; AS 50 mg and AQ 200 mg)
Number of subjects: 60
Study 20949263 — intervention group
Group type: COMPARATOR
Intervention: Non-fixed dose combination (Arsuamoon AS 50 mg and Flavoquine AQ 200 mg)
Number of subjects: 60
Study 19395364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 microg every 3 h for five doses
Number of subjects: 100
Study 19395364 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 3 h for five doses
Number of subjects: 100
Study 16374601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam administration
Number of subjects: 0
Study 15223867 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed CAP score
Number of subjects: 67
Study 11252467 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g Cr + 20 g glucose per day, n=9)
Number of subjects: 18
Study 11252467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 g glucose per day, n=9)
Number of subjects: 18
Study 9253339 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment (L-thyroxine) at a mean dose of 2.8 +/- 0.9 micrograms/kg (0.192 +/- 0.058 mg/day) for a mean duration of 9.2 +/- 5.4 yr
Number of subjects: 17
Study 8323210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform water 5 ml/day with 1 mg of iodine for 20 weeks
Number of subjects: 55
Study 8323210 — intervention group
Group type: COMPARATOR
Intervention: Chloroform water 5 ml/day (placebo)
Number of subjects: 55
Study 3162993 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal equilibration (O group)
Number of subjects: 30
Study 3162993 — intervention group
Group type: COMPARATOR
Intervention: Routine stomatognathic treatment including an occlusal splint (S group)
Number of subjects: 30
Study 30302783 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure (n = 40)
Number of subjects: 75
Study 28760384 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin 10 μg
Number of subjects: 393
Study 28760384 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin 30 μg
Number of subjects: 393
Study 28760384 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin 100 μg
Number of subjects: 393
Study 28760384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 25524261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse endoscopists
Number of subjects: 731
Study 25524261 — intervention group
Group type: COMPARATOR
Intervention: Medical endoscopists
Number of subjects: 731
Study 23294908 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN+MTX
Number of subjects: 300
Study 23294908 — intervention group
Group type: COMPARATOR
Intervention: DMARD+MTX
Number of subjects: 300
Study 21852813 — intervention group
Group type: COMPARATOR
Intervention: Weight loss intervention (6-month exercise-based program)
Number of subjects: 23
Study 21852813 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain after weight loss
Number of subjects: 23
Study 19643544 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 257
Study 19643544 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 257
Study 19643544 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant
Number of subjects: 257
Study 17223416 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 17223416 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 15275728 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR intracavitary brachytherapy
Number of subjects: 237
Study 15275728 — intervention group
Group type: COMPARATOR
Intervention: HDR intracavitary brachytherapy
Number of subjects: 237
Study 11207159 — intervention group
Group type: COMPARATOR
Intervention: Diet History Questionnaire (DHQ)
Number of subjects: 1350
Study 11207159 — intervention group
Group type: COMPARATOR
Intervention: Prostate, Lung, Colorectal, and Ovarian (PLCO) FFQ
Number of subjects: 1350
Study 9476038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg once daily for 7 days)
Number of subjects: 10
Study 9476038 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 10
Study 8201068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral family intervention (CBFI)
Number of subjects: 44
Study 8201068 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric care (SPC)
Number of subjects: 44
Study 3661953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taming with suxamethonium (4 mg i.v. after induction, remaining dose applied one minute later)
Number of subjects: 132
Study 3661953 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment with pancuronium bromide (2 mg 3 min prior to suxamethonium 1.5 mg/kg)
Number of subjects: 132
Study 3661953 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 132
Study 31628475 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg nicotine per g tobacco)
Number of subjects: 58
Study 31628475 — intervention group
Group type: COMPARATOR
Intervention: Normal Nicotine Content (NNC) cigarettes (15.8 mg nicotine per g tobacco)
Number of subjects: 58
Study 29445514 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training using HappyNeuron Pro software, 30 minutes, three times a week for 12 weeks
Number of subjects: 0
Study 29445514 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving social interaction via study and home visits
Number of subjects: 0
Study 26864207 — intervention group
Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 20 000 AUeq/ml
Number of subjects: 290
Study 26864207 — intervention group
Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 50 000 AUeq/ml
Number of subjects: 290
Study 26864207 — intervention group
Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 6667 AUeq/ml
Number of subjects: 290
Study 26864207 — intervention group
Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 100 000 AUeq/ml
Number of subjects: 290
Study 26864207 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 290
Study 25072595 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT1 gel formulation plus standard-of-care (SOC) protocols
Number of subjects: 0
Study 25072595 — intervention group
Group type: COMPARATOR
Intervention: SOC protocols alone
Number of subjects: 0
Study 25072595 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT1 therapy
Number of subjects: 0
Study 24276102 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel device for maintaining balance during CPR
Number of subjects: 40
Study 24276102 — intervention group
Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 40
Study 21840002 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (240 mg/day of zinc as zinc gluconate)
Number of subjects: 40
Study 21840002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19019730 — intervention group
Group type: EXPERIMENTAL
Intervention: Crataegus extract WS 1442 (900 mg/day)
Number of subjects: 2681
Study 19019730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2681
Study 16371498 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme with ice applied for 10 minutes after exercises, five times a week for four weeks.
Number of subjects: 40
Study 16371498 — intervention group
Group type: COMPARATOR
Intervention: Exercise programme alone (without ice), five times a week for four weeks.
Number of subjects: 40
Study 12631182 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis with psychological stress (stress group)
Number of subjects: 27
Study 12631182 — intervention group
Group type: COMPARATOR
Intervention: Experimental gingivitis without psychological stress (control group)
Number of subjects: 27
Study 11106919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg) plus GHRH (100 microg, i.v.)
Number of subjects: 23
Study 11106919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg) plus GHRH (100 microg, i.v.)
Number of subjects: 23
Study 11106919 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus GHRH (100 microg, i.v.)
Number of subjects: 23
Study 8827178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiologic studies
Number of subjects: 0
Study 8827178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent changes in causal factors and diagnostic technological advances
Number of subjects: 0
Study 8827178 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued epidemiologic monitoring
Number of subjects: 0
Study 1545097 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalative challenge tests with powdered latex gloves
Number of subjects: 70
Study 1545097 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to natural latex
Number of subjects: 70
Study 1545097 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiatively cross‐linked, 'hypoallergenic' latex preparation
Number of subjects: 70
Study 1545097 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial-latex RAST disks (Pharmacia)
Number of subjects: 70
Study 1545097 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex IgE RAST and latex skin prick test correlation
Number of subjects: 70
Study 6375711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantle radiotherapy followed by 6 courses of adjuvant chemotherapy with mustine, vinblastine, prednisolone and procarbazine (MVPP)
Number of subjects: 114
Study 6375711 — intervention group
Group type: COMPARATOR
Intervention: Mantle radiotherapy alone
Number of subjects: 114
Study 31423757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2WALK (sitting with 2‐min light‐intensity walking breaks every 30 min)
Number of subjects: 15
Study 31423757 — intervention group
Group type: EXPERIMENTAL
Intervention: 8WALK (sitting with 8‐min light‐intensity walking breaks every 2 h)
Number of subjects: 15
Study 31423757 — intervention group
Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 15
Study 29470731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 64
Study 29470731 — intervention group
Group type: COMPARATOR
Intervention: Personalized conservative treatment (PCT)
Number of subjects: 64
Study 26762378 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 26762378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24574235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 195
Study 22211635 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention targeting young low-SES disruptive boys (social skills, parental practices, teacher support)
Number of subjects: 250
Study 22211635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 20811918 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% lidocaine spray 10 min prior to intubation and ETTs lubricated with normal saline (Group E)
Number of subjects: 527
Study 20811918 — intervention group
Group type: COMPARATOR
Intervention: 8% lidocaine spray immediately before intubation and ETTs lubricated with normal saline (Group B)
Number of subjects: 527
Study 20811918 — intervention group
Group type: COMPARATOR
Intervention: 8% lidocaine spray immediately before intubation and ETTs lubricated with 2% lidocaine gel (Group A)
Number of subjects: 527
Study 20811918 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine spray and ETTs lubricated with normal saline (Group C)
Number of subjects: 527
Study 20811918 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine spray and ETTs lubricated with 2% lidocaine gel (Group D)
Number of subjects: 527
Study 17353400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS, 700 microg
Number of subjects: 315
Study 17353400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS, 350 microg
Number of subjects: 315
Study 17353400 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 315
Study 17353400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (both dosages)
Number of subjects: 315
Study 14998595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (4h group session + individual nurse and physiotherapist sessions)
Number of subjects: 62
Study 14998595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 62
Study 14998595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 62
Study 11758183 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d + MPA 2 mg/d + Ca‐D 600 mg/d
Number of subjects: 60
Study 11758183 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/d + MPA 2 mg/d + Ca‐D 600 mg/d
Number of subjects: 60